Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD

References

• Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet364(9435), 709–721 (2004).
   PubMed Web of Science ®Google Scholar
• Chung KF, Caramori G, Adcock IM. Inhaled corticosteroids as combination therapy with β-adrenergic agonists in airways disease: present and future. Eur. J. Clin. Pharmacol.65(9), 853–871 (2009).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Emerging pharmacotherapies for COPD. Chest134(6), 1278–1286 (2008).
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Gauvreau G. Phosphodiesterase-4 inhibition in COPD. Lancet374(9691), 665–667 (2009).
   PubMedGoogle Scholar
• Frielle T, Caron MG, Lefkowitz RJ. Properties of the β 1- and β 2-adrenergic receptor subtypes revealed by molecular cloning. Clin. Chem.35(5), 721–725 (1989).
   Google Scholar
• Emorine LJ, Marullo S, Delavier-Klutchko C, Kaveri SV, Durieu-Trautmann O, Strosberg AD. Structure of the gene for human β 2-adrenergic receptor: expression and promoter characterization. Proc. Natl Acad. Sci. USA84(20), 6995–6999 (1987).
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Decramer M et al. Bronchodilator responsiveness in patients with COPD. Eur. Respir. J.31(4), 742–750 (2008).
   PubMed Web of Science ®Google Scholar
• Waldeck B. β-adrenoceptor agonists and asthma – 100 years of development. Eur. J. Pharmacol.445(1–2), 1–12 (2002).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br. J. Pharmacol.155(3), 291–299 (2008).
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax63(9), 831–838 (2008).
   PubMed Web of Science ®Google Scholar
• Beeh KM, Beier J. The short, the long and the ‘ultra-long’: why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv. Ther.27(3), 150–159 (2010).
   PubMed Web of Science ®Google Scholar
• Halpin DM, Tashkin DP. Defining disease modification in chronic obstructive pulmonary disease. COPD6(3), 211–225 (2009).
   PubMedGoogle Scholar
• van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax55(4), 289–294 (2000).
   PubMed Web of Science ®Google Scholar
• Littner MR, Ilowite JS, Tashkin DP et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.161(4 Pt 1), 1136–1142 (2000).
   PubMed Web of Science ®Google Scholar
• Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest118(5), 1294–1302 (2000).
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J.19(2), 217–224 (2002).
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther.23(8), 1296–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Dahl R, Chung KF, Buhl R et al. Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax65(6), 473–479 (2010).
   PubMed Web of Science ®Google Scholar
• Rennard S, Bantje T, Centanni S et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Resp. Med.102(7), 1033–1044 (2008).
   PubMed Web of Science ®Google Scholar
• Beier J, Chanez P, Martinot JB et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily β(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm. Pharmacol. Ther.20(6), 740–749 (2007).
   PubMed Web of Science ®Google Scholar
• Bauwens O, Ninane V, Van de Maele B et al. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr. Med. Res. Opin.25(2), 463–470 (2009).
   PubMed Web of Science ®Google Scholar
• Pavkov R, Mueller S, Fiebich K et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr. Med. Res. Opin.26(11), 2527–2533 (2010).
   PubMed Web of Science ®Google Scholar
• Battram C, Charlton SJ, Cuenoud B et al.In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled β(2) adrenoceptor agonist with a 24-h duration of action. J. Pharmacol. Exp. Ther.317(2), 762–770 (2006).
   PubMed Web of Science ®Google Scholar
• Naline E, Trifilieff A, Fairhurst RA, Advenier C, Molimard M. Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi. Eur. Respir. J.29(3), 575–581 (2007).
   PubMed Web of Science ®Google Scholar
• Sturton RG, Trifilieff A, Nicholson AG, Barnes PJ. Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J. Pharmacol. Exp. Ther.324(1), 270–275 (2008).
   PubMed Web of Science ®Google Scholar
• Sayers I, Hawley J, Stewart CE et al. Pharmacogenetic characterization of indacaterol, a novel β 2-adrenoceptor agonist. Br. J. Pharmacol.158(1), 277–286 (2009).
   PubMed Web of Science ®Google Scholar
• Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A. Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma. Eur. Respir. J.29(5), 871–878 (2007).
   PubMed Web of Science ®Google Scholar
• LaForce C, Korenblat P, Osborne P, Dong F, Higgins M. 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol. Curr. Med. Res. Opin.25(10), 2353–2359 (2009).
   PubMed Web of Science ®Google Scholar
• Chuchalin AG, Tsoi AN, Richter K et al. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir. Med.101(10), 2065–2075 (2007).
   PubMed Web of Science ®Google Scholar
• Baur F, Beattie D, Beer D et al. The identification of indacaterol as an ultralong-acting inhaled β2-adrenoceptor agonist. J. Med. Chem.53(9), 3675–3684 (2010).
   PubMed Web of Science ®Google Scholar
• Lombardi D, Cuenoud B, Kramer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur. J. Pharm. Sci.38(5), 533–547 (2009).
   PubMed Web of Science ®Google Scholar
• Summerhill S, Stroud T, Nagendra R, Perros-Huguet C, Trevethick M. A cell-based assay to assess the persistence of action of agonists acting at recombinant human β(2) adrenoceptors. J. Pharmacol. Toxicol. Methods58(3), 189–197 (2008).
   PubMedGoogle Scholar
• Feldman G, Siler T, Prasad N et al. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm. Med.10, 11 (2010).
   PubMed Web of Science ®Google Scholar
• Yang WH, Martinot JB, Pohunek P et al. Tolerability of indacaterol, a novel once-daily β2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study. Ann. Allergy Asthma Immunol.99(6), 555–561 (2007).
   PubMed Web of Science ®Google Scholar
• Tarral A, Fauchoux N, Knight H. Safety and tolerability of multiple-dose indacaterol, a novel β2-agonist, in patients with mild asthma [abstract]. Eur. Respir. J.26, 253S (2005).
   Google Scholar
• Duvauchelle T, Elharrar B, Knight H. Single-dose indacaterol, a novel 24-h β2-agonist, is well tolerated in patients with mild asthma [abstract]. Eur. Respir. J.26, 253S (2005).
   Google Scholar
• Barnes PJ, Pocock SJ, Magnussen H et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm. Pharmacol. Ther.23(3), 165–171 (2010).
   PubMed Web of Science ®Google Scholar
• Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, Pascoe S. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm. Pharmacol. Ther.22(6), 492–496 (2009).
   PubMed Web of Science ®Google Scholar
• Donohue JF, Fogarty C, Lotvall J et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am. J. Respir. Crit. Care Med.182(2), 155–162 (2010).
   PubMed Web of Science ®Google Scholar
• Kornmann O, Dahl R, Centanni S et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur. Respir. J. DOI: 10.1183/09031936.00045810 (2010) (Epub ahead of print).
   Google Scholar
• Beeh KM, Khindri S, Eeg M, Drollman AF. Effect of indacaterol maleate on dynamic lung hyperinflation in patients with COPD. Eur. Respir. J.34, 4357 (2009).
   Google Scholar
• O’Donnell DE, Casaburi R, Swales J, Emery C, Kramer B. Effect of indacaterol on exercise endurance in patients with moderate-to-severe COPD. Am. J. Respir. Crit. Care Med.181, A4431 (2010).
   Google Scholar
• Beeh KM, Beier J. Indacaterol, a novel inhaled, once-daily, long-acting β2-agonist for the treatment of obstructive airways diseases. Erratum appears in Adv.Ther. 2009 6(8): 812 Note: Dosage error in article text. Adv.Ther.26(7), 691–699 (2009).
   PubMedGoogle Scholar
• Brookman LJ, Knowles LJ, Barbier M, Elharrar B, Fuhr R, Pascoe S. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. Curr. Med. Res. Opin.23(12), 3113–3122 (2007).
   PubMed Web of Science ®Google Scholar
• Kanniess F, Boulet LP, Pierzchala W, Cameron R, Owen R, Higgins M. Efficacy and safety of indacaterol, a new 24-hour β2-agonist, in patients with asthma: a dose-ranging study. J. Asthma45(10), 887–892 (2008).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Segreti A, Matera MG. Novel bronchodilators in asthma. Curr. Opin. Pulm. Med.16(1), 6–12 (2010).
   PubMed Web of Science ®Google Scholar
• Celli BR, Thomas NE, Anderson JA et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med.178(4), 332–338 (2008).
   PubMed Web of Science ®Google Scholar